|Bid||11.11 x 1400|
|Ask||12.10 x 1100|
|Day's Range||11.54 - 12.09|
|52 Week Range||10.32 - 29.97|
|Beta (5Y Monthly)||1.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.71|
Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WALTHAM, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Monday, August 10, 2020. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a company update. Conference Call Information: Date: Monday, August 10, 2020 Time: 8:30 a.m. ET Domestic Dial-In Number: (866) 323-7965 International Dial-In Number: (346) 406-0961 Conference ID: 6334188A replay of the conference call will be available on August 10 at 11:30 a.m. ET and live audio webcast of the call will be archived on the Company's website for ninety days. To access the replay, dial (855) 859-2056 U.S. or (404) 537-3406 for International, using conference ID number 6334188. The live audio webcast of the call can be accessed from the Investors section of the Company’s website, https://ir.radiuspharm.com/events-and-presentations. The full text of the announcement and financial results will also be available on the Company’s website.About RadiusRadius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius’ lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes the investigational use of abaloparatide injection for the treatment of men with osteoporosis, an investigational abaloparatide-patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer , outlicensed to Menarini Group; and the investigational drug RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in hormone-receptor positive breast cancer. For more information, please visit www.radiuspharm.com.Investor & Media Relations Contact: Elhan Webb, CFA Email: email@example.com. Phone: 617-551-4011
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 23) * Abbott Laboratories (NYSE: ABT) * ABIOMED, Inc. (NASDAQ: ABMD) * Acceleron Pharma Inc (NASDAQ: XLRN) * Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) * Arbutus Biopharma Corp (NASDAQ: ABUS)( won a patent challenge brought about by Moderna Inc (NASDAQ: MRNA)) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) * Champions Oncology Inc (NASDAQ: CSBR) * Fulgent Genetics Inc (NASDAQ: FLGT) * Genocea Biosciences Inc (NASDAQ: GNCA) (reacted to its second-quarter results) * Hologic, Inc. (NASDAQ: HOLX) * Intuitive Surgical, Inc. (NASDAQ: ISRG) * Ligand Pharmaceuticals Inc. (NASDAQ: LGND) * Medpace Holdings Inc (NASDAQ: MEDP) * NeoGenomics, Inc. (NASDAQ: NEO) * Penumbra Inc (NYSE: PEN) * Quest Diagnostics Inc (NYSE: DGX) * RENALYTIX AI ADR (NASDAQ: RNLX) (IPOed Friday) * ResMed Inc. (NYSE: RMD) * Silk Road Medical Inc (NASDAQ: SILK) * Tandem Diabetes Care Inc (NASDAQ: TNDM) * West Pharmaceutical Services Inc. (NYSE: WST)(reacted to its second quarter results) * Zoetis Inc (NYSE: ZTS)Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 23) * ALX Oncology Holdings Inc (NASDAQ: ALXO) (IPOed last Friday) * Forma Therapeutics Holdings Inc (NASDAQ: FMTX) * Fusion Pharmaceuticals Inc (NASDAQ: FUSN) * Nkarta Inc (NASDAQ: NKTX) * Chanticleer Holdings (NASDAQ: SONN)Related Link: 5 Coronavirus Stock Valuations Surging During The Pandemic Stocks In Focus Radius Health Out-licenses Breast Cancer Drug For Up To $350M Radius Health Inc (NASDAQ: RDUS) said it has entered into an exclusive global license agreement with the Menarini Group for the development and commercialization of elacestrant, an investigational asset that is currently being evaluated in a Phase 3 study as a hormonal treatment for postmenopausal women and men with advanced ER+/HER2- breast cancer.Radius will receive an upfront payment of $30 million and up to $320 million in additional payments based on the successful achievement of future development and sales milestones. The company is also eligible for tiered, low to mid-teen percentage royalty payments on global net sales.In pre-market trading Friday, Radius Health shares were rising 9.36% to $13.90.BioMarin Makes Regulatory Submission For Bone Growth Disorder Drug In Europe BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced the submission of a Marketing Authorization Application to the European Medicines Agency for vosoritide, an investigational, once-daily injection analog of C-type Natriuretic Peptide for children with achondroplasia, the most common form of disproportionate short stature in humans.Subject to completion of EMA's validation check, BioMarin said it anticipates the start of the MAA review to commence in August.Novavax Delays Phase 1 Data Readout, Strikes Coronavirus Manufacturing Deal Novavax, Inc. (NASDAQ: NVAX) said it will release the Phase 1 data, which will consist of preliminary immunogenicity and safety results, during the first week of August, as opposed to the earlier timeframe of July. The Phase 2 portion to assess immunity, safety, and COVID-19 disease reduction is expected to begin shortly thereafter, it added.Novavax also announced an agreement with FUJIFILM Diosynth Biotechnologies, a CDMO, to manufacture bulk drug substance for NVX-CoV2373, the former's COVID-19 vaccine candidate. Fujifilm's site in Morrisville, North Carolina has begun production of the first batch of NVX-CoV2373, the companies said.View more earnings on IBBThe stock was slipping 4% to $134 in pre-market trading.Arcturus Announces Preliminary Deal to Supply Covid-19 Vaccine Candidate to Israel Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced a binding term sheet with the Israeli Ministry of Health to supply its COVID-19 vaccine candidate, LUNAR-COV19. The parties intend to finalize a comprehensive supply agreement within 30 days, the company said.Earnings LeMaitre Vascular Inc's (NASDAQ: LMAT) second-quarter sales fell a smaller than expected 16% to $24.9 million and EPS fell from 23 cents to 17 cents. The company issued an upbeat guidance for the third quarter.The stock was advancing 12.24% to $32.47 in pre-market trading Friday.Edwards Lifesciences Corp's (NYSE: EW) second-quarter sales fell 15% to $925 million, and adjusted EPS fell 26% to 34 cents. The bottom-line exceeded estimates. The company reiterated its full-year sales guidance of $4 billion to $4.5 billion, and increased its adjusted EPS guidance from $1.58 to $1.75 to $1.75 to $1.95. The sales guidance was in line and the bottom-line guidance exceeded estimates.On The Radar IPOs iTeos Therapeutics, a clinical-stage biopharma engaged in the development of a new generation of highly differentiated immuno-oncology therapeutics for patients, priced its initial public offering, or IPO, of 10.586 million shares at $19.00 per share, above the estimated price range of $16-$18. The shares will begin trading on the Nasdaq under the ticker symbol ITOS. The offering is expected to generate gross proceeds of $201.1 million.Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, priced its IPO of 11 million shares at $19 per share, for generating gross proceeds of $209 million. The company had earlier estimated a price range of $17-$18. The shares will commence trading on the Nasdaq under the ticker symbol NRIX.Inozyme Pharma, Inc, a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization, priced its upsized IPO of 7 million shares at $16 per share, for raising gross proceeds of $112 million. The shares are expected to commence trading on the Nasdaq under the ticker symbol INZY.See more from Benzinga * The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results * The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat * The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.